Enrolling by invitationPhase 3

Long-term safety of riliprubart for chronic inflammatory demyelinating polyneuropathy

Tests riliprubart over the long term in adults with chronic inflammatory demyelinating polyneuropathy.

Plain-language title generated from the registry record
Registry title: Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

Key facts

Where: Taipei, TaiwanSee the site
Phase: Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with CIDP who are taking riliprubart and finished Part B of one of three earlier riliprubart studies. They want to keep getting the treatment.

Age: 18 years or older
Sex: Men and women
Disease stage: Chronic inflammatory demyelinating polyneuropathy (CIDP)
Earlier treatment: Must be taking riliprubart now and have finished Part B of study PDY16744, EFC17236 or EFC18156. People in Part C of PDY16744 can join after the Part C End of Treatment visit.

Main reasons for not taking part

Pregnancy or breastfeeding
Diagnosis of systemic lupus erythematosus (SLE)
Allergy to riliprubart or severe allergic reaction to a humanized or murine monoclonal antibody
Living in an institution because of a regulatory or legal order
Judged by the investigator as unable to take part

Read by machine on 12 November 2026.

Where in Taiwan

TaipeiHospital not named in the registryNo longer taking part

Questions to ask the study team

How often do I need to come in, and for how long each time?
Are travel costs paid?
Can I keep my own doctor?
What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it: Sanofi
Trial code: NCT06859099 EU 2024-517032-22-00
Record updated: 27 October 2026
Original description: This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating polyneuropathy (CIDP) who have completed Part B in 1 of 3 parent studies (PDY16744, EFC17236, or EFC18156) and wish to continue treatment with riliprubart. Up to approximately 300 participants will be enrolled to continue receiving treatment with riliprubart. The duration of participation for each participant will be up to approximately 4 years, including posttreatment follow-up. The treatment duration will be up to approximately 3 years. A participant who discontinues riliprubart treatment at any time during the study will be followed for safety for a minimum of 55 weeks after the last dose of riliprubart received.Read full original descriptionShow less
Long-term Extension Study to Evaluate the Safety and Efficacy of Riliprubart (SAR445088) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating polyneuropathy (CIDP) who have completed Part B in 1 of 3 parent studies (PDY16744, EFC17236, or EFC18156) and wish to continue treatment with riliprubart. Up to approximately 300 participants will be enrolled to continue receiving treatment with riliprubart. The duration of participation for each participant will be up to approximately 4 years, including posttreatment follow-up. The treatment duration will be up to approximately 3 years. A participant who discontinues riliprubart treatment at any time during the study will be followed for safety for a minimum of 55 weeks after the last dose of riliprubart received.
Inclusion: Participants are eligible to be included in the study only if all of the following criteria apply:; Participants with chronic inflammatory demyelinating polyneuropathy (CIDP) currently receiving riliprubart who completed treatment in Part B of Study PDY16744, Study EFC17236, or Study EFC18156. (Participants receiving riliprubart in Part C of PDY16744 are eligible after completing the Part C End of Treatment visit.); All participants must agree to use contraception methods during and after the study as required. Contraceptive use by men and women participating in the study should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies; Participant must be capable of giving signed informed consent as described in Appendix 1 of the protocol, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Exclusion: History of any hypersensitivity to riliprubart or any of its components, or severe allergic or anaphylactic reaction to any humanized or murine monoclonal antibody; Unsuitability for participation as judged by the Investigator, whatever the reason, including: medical or clinical condition, potential risk of participant noncompliance with study procedures, or any other clinically significant change in the participants' medical condition; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial; Pregnancy, defined as a positive result of a highly sensitive urine or serum pregnancy test, or lactation; Participants are excluded from the study if any of the following criteria apply:; Clinical diagnosis of systemic lupus erythematosus (SLE); Any country-related specific regulation that would prevent the participant from entering the study; Accommodation in an institution because of regulatory or legal order; for instance, a prisoner or participant who is legally institutionalized.
ClinicalTrials.gov NCT06859099 · EU CTIS 2024-517032-22-00